Cantor Fitzgerald reiterated their buy rating on shares of Advaxis, Inc. (NASDAQ:ADXS) in a research report report published on Monday. The brokerage currently has a $19.00 price objective on the biotechnology company’s stock.

“Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda.”,” Cantor Fitzgerald’s analyst commented.

Several other equities research analysts have also recently commented on ADXS. BidaskClub cut Advaxis from a hold rating to a sell rating in a research note on Monday, July 31st. ValuEngine lowered Advaxis from a sell rating to a strong sell rating in a research report on Tuesday, August 8th. Finally, HC Wainwright restated a buy rating and issued a $23.00 price target on shares of Advaxis in a research report on Friday, September 15th.

Shares of Advaxis (ADXS) opened at 4.49 on Monday. The stock’s 50 day moving average price is $6.19 and its 200 day moving average price is $7.33. The stock’s market capitalization is $184.38 million. Advaxis has a one year low of $3.91 and a one year high of $12.66.

Advaxis (NASDAQ:ADXS) last released its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. On average, analysts forecast that Advaxis will post ($2.23) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/28/advaxis-adxs-buy-rating-reiterated-at-cantor-fitzgerald.html.

In other news, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the firm’s stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $4.42, for a total value of $5,477,807.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. 7.21% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Stevens Capital Management LP bought a new position in shares of Advaxis in the 1st quarter worth $105,000. Voya Investment Management LLC boosted its position in shares of Advaxis by 20.3% in the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 2,975 shares during the last quarter. Cutler Capital Management LLC bought a new position in shares of Advaxis in the 2nd quarter worth $130,000. American International Group Inc. boosted its position in shares of Advaxis by 7.6% in the 1st quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 1,459 shares during the last quarter. Finally, Northern Capital Management LLC boosted its position in shares of Advaxis by 14.6% in the 2nd quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 2,650 shares during the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.